Ipsen to acquire rights to Santhera's fipamezole
This article was originally published in Scrip
Executive Summary
In a bid to beef up its research pipeline Ipsen, the French speciality pharma company, is paying Santhera Pharmaceuticals €13 million up front for the rights to its adrenergic alpha-2 receptor antagonist fipamezole outside North America and Japan.